|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2005-9-23
|
|
pubmed:abstractText |
Since the p53 gene has been identified as a determinant of response to chemotherapy in ovarian carcinoma in previous studies, we investigated the significance of the p53 status in response to topotecan as second-line therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
154-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16127286-Aged,
pubmed-meshheading:16127286-Antineoplastic Agents,
pubmed-meshheading:16127286-Carcinoma,
pubmed-meshheading:16127286-Drug Resistance, Neoplasm,
pubmed-meshheading:16127286-Female,
pubmed-meshheading:16127286-Genes, p53,
pubmed-meshheading:16127286-Humans,
pubmed-meshheading:16127286-Middle Aged,
pubmed-meshheading:16127286-Neoplasm Recurrence, Local,
pubmed-meshheading:16127286-Ovarian Neoplasms,
pubmed-meshheading:16127286-Polymerase Chain Reaction,
pubmed-meshheading:16127286-Predictive Value of Tests,
pubmed-meshheading:16127286-Retrospective Studies,
pubmed-meshheading:16127286-Topotecan,
pubmed-meshheading:16127286-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma.
|
|
pubmed:affiliation |
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
